Overview Snapshot A 30-year-old woman presents to an asthma specialist for management of her moderate-to-severe asthma. She is currently using fluticasone and salmeterol inhalers. She continues to experience 2-3 episodes of asthma exacerbations a week with night-time awakenings and several trips to the emergency room in the past month. Her physician considers adding a targeted therapy that inhibits leukotrienes to her regimen. Introduction Arachidonic acid pathway transforms arachidonic acid into a variety of inflammatory mediators, including leukotrienes, prostacyclin, and prostaglandins Many anti-inflammatory agents, including asthma medications, target downstream molecules in this pathway Lipoxygenase pathway products LTB4 ↑ neutrophil chemotaxis LTC4, LTD4, and LTE4 ↑ bronchial tone montelukast and zafirlukast inhibit these products Prostacyclin PGI2 ↓ platelet aggregation vasodilation epoprostenol is a PGI2 analogue Prostaglandins PGE1 vasodilation also known as alprostadil used to maintain a patent ductus arteriosus in newborns with ductal-dependent congenital heart disease PGE2 ↑ uterine tone dinoprostone is a PGE2 analogue PGF2α ↑ uterine tone carboprost is a PGF2α analogue Thromboxane TXA2 ↑ platelet aggregation ↑ vasoconstriction
QUESTIONS 1 of 1 1 Previous Next Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK
All Videos (2) Login to View Community Videos Login to View Community Videos Aracidonic Acid Cont. MSK - Arachidonic Acid Products E 2/15/2015 35 views 0.0 (0) Login to View Community Videos Login to View Community Videos Aracidonic Acid MSK - Arachidonic Acid Products E 2/15/2015 47 views 0.0 (0)